Long-term IGF-I treatment of children with Laron syndrome increases adiposity

被引:42
|
作者
Laron, Z
Ginsberg, S
Lilos, P
Arbiv, M
Vaisman, N
机构
[1] Schneider Childrens Med Ctr, Endocrinol & Diabet Res Unit, IL-49202 Petah Tiqwa, Israel
[2] Sourasky Med Ctr, Dept Clin Nutr, Tel Aviv, Israel
[3] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
关键词
Laron syndrome; primary GH insensitivity; body composition; obesity; IGF-I treatment; IGF-I adipogenic effect;
D O I
10.1016/j.ghir.2005.12.001
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Laron syndrome (LS) is an autosomal recessive disease caused by deletions or mutations in the GH receptor gene leading to an inability of insulin-like growth factor I (IGF-I) generation. Among the major resulting body changes are dwarfism and obesity. The only effective treatment is daily administration of biosynthetic IGF-I. Body composition determination by DEXA (dual energy X-ray absorptiornetry) of three girls with LS treated by IGF-I for 1, 3 and 11 1/2 years, respectively, revealed that concomitantly with the increase in growth there was a significant increase in body adipose tissue to double or triple the normal values. Due to the underdevelopment of the muscular and skeletal systems body mass index (BMI) did not accurately reflect the degree of obesity. In conclusion, IGF-I similar to insulin, exerts an adipogenic effect. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:61 / 64
页数:4
相关论文
共 50 条
  • [1] Commentary - The essential role of IGF-I: Lessons from the long-term study and treatment of children and adults with Laron syndrome
    Laron, Z
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (12): : 4397 - 4404
  • [2] 3 YEAR IGF-I TREATMENT OF CHILDREN WITH LARON-SYNDROME
    KLINGER, B
    LARON, Z
    [J]. JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 1995, 8 (03): : 149 - 158
  • [3] Serum insulin-like growth factor-I (IGF-I) levels during long-term IGF-I treatment of children and adults with primary GH resistance (Laron syndrome)
    Laron, Z
    Klinger, B
    Silbergeld, A
    [J]. JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 1999, 12 (02): : 145 - 152
  • [4] LARON SYNDROME DUE TO A POSTRECEPTOR DEFECT - RESPONSE TO IGF-I TREATMENT
    LARON, Z
    KLINGER, B
    ESHET, R
    KANETI, H
    KARASIK, A
    SILBERGELD, A
    [J]. ISRAEL JOURNAL OF MEDICAL SCIENCES, 1993, 29 (12): : 757 - 763
  • [5] IGF-I replacement therapy in children with congenital IGF-I deficiency (Laron syndrome) maintains heart dimension and function
    Scheinowitz, Mickey
    Feinberg, Micha S.
    Laron, Zvi
    [J]. GROWTH HORMONE & IGF RESEARCH, 2009, 19 (03) : 280 - 282
  • [6] IGF-I TREATMENT OF ADULT PATIENTS WITH LARON SYNDROME - PRELIMINARY-RESULTS
    LARON, Z
    KLINGER, B
    [J]. CLINICAL ENDOCRINOLOGY, 1994, 41 (05) : 631 - 638
  • [7] Long-term physical training increases liver IGF-I in diabetic rats
    Leme, J. A. C. A.
    Silveira, R. F.
    Gomes, R. J.
    Moura, R. F.
    Sibuya, C. A.
    Mello, M. A. R.
    Luciano, E.
    [J]. GROWTH HORMONE & IGF RESEARCH, 2009, 19 (03) : 262 - 266
  • [8] Postprandial Hyperglycemia Corrected by IGF-I (Increlex®) in Laron Syndrome
    Latrech, Hanane
    Simon, Albane
    Beltrand, Jacques
    Souberbielle, Jean-Claude
    Belmejdoub, Ghizlane
    Polak, Michel
    [J]. HORMONE RESEARCH IN PAEDIATRICS, 2012, 78 (03): : 193 - 200
  • [9] Serum leptin in obese patients with Laron syndrome before and during IGF-I treatment
    Laron, Z
    Silbergeld, A
    Lilos, P
    Blum, FWF
    [J]. JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 1998, 11 (05): : 653 - 656
  • [10] Long-term treatment of growth hormone insensitivity syndrome with IGF-I - Results of the European multicentre study
    Ranke, MB
    Savage, MO
    Chatelain, PG
    Preece, MA
    Rosenfeld, RG
    Wilton, P
    [J]. HORMONE RESEARCH, 1999, 51 (03) : 128 - 134